news
AbbVie to buy neuroscience specialist Cerevel Therapeutics for $8.7bn
AbbVie plans to acquire neuroscience specialist Cerevel Therapeutics for $45 per share, or around $8.7 billion.
List view / Grid view
Psychosis
article
Embedding inclusion in pharmaceutical design
In this article, Included’s Raafi-Karim Alidina explores biases in product design, outlining how they impact pharmaceuticals as well as technologies, and practical steps to enhance diversity and ensure inclusion.
news
First AI designed Alzheimer’s drug to enter clinical trials
The trial of DSP-0038, an Alzheimer’s disease psychosis drug designed using artificial intelligence, will assess its ability to improve the behavioural and psychological symptoms of dementia.
news
Medical cannabis: what UK doctors need to know
Cannabinoids, their potential therapeutic uses and the research needed for medical cannabis were the topics of discussion at the ‘Medical cannabis: what UK doctors need to know’ event held last week.
news
CBD may protect against psychiatric risk from high-THC cannabis strains
Neuroscientists have found that cannabidiol reduces symptoms such as impaired memory in adolescent mice simultaneously exposed to THC...
news
Study examines link between marijuana and vulnerability to psychosis
Going from an occasional user of marijuana to a weekly or daily user increases an adolescent’s risk of having recurrent psychotic-like experiences by 159%, according to a new Canadian study...
